Yuanda Shuyang has established an advanced technological innovation system and an industry-academia-research cooperation platform, to conduct preclinical exploration, research, and collaboration to accelerate innovation and benefit more patients.

• 
  Protein Separation and Purification Platform

  Over 1,300 square meters of process development laboratories
  Over 1,000 square meters of GMP pilot workshops
  Sichuan Blood Products Engineering Technology Research Center
  

• 
  Plasma Screening Platform for hyperimmune globulin

  P2 laboratory
  New methods and new technologies to improve screening yield
  Cellular neutralization method (new hyperimmune globulin)

• 
  Sterile Lyophilized Preparation Platform

  Sterile filling line
  Experimental freeze dryer, differential scanning calorimeter
  Freeze-drying process development, small-scale trial production

• 
  Virus Inactivation Process Platform

  Develop virus inactivation process combined with purification and preparation platforms
  P2 laboratory, model virus cultivation
  Self-verification of virus inactivation effectiveness

• 
  Quality Standard Research Platform

  Over 1,405 square meters of quality research laboratories
  Routine physicochemical testing of biological products
  Testing of activity indicators for blood products

• National 863 Program

  The main entity responsible for the “Comprehensive Utilization of Plasma and Development of New Products such as hyerimmune globulin”: Achieved technological innovations in the processes of 10% human immunoglobulin for intravenous injection, high-purity human coagulation factor Ⅷ, and high-purity human coagulation factor Ⅸ, reaching a leading level in China.

• Ministry of Science and Technology Policy Guidance Program, and Sichuan Province Science and Technology Achievement Transformation Project

  Shuyang’s human hepatitis B immunoglobulin (pH4) for intravenous injection has been listed as a “National Key New Product.” Shuyang’s \human immunoglobulin (pH4) for intravenous injection and human albumin have also won the Sichuan Province Innovation Achievements Excellence Award.
  

• The Third Batch of Applied Technology Research and Development Projects in Sichuan Province, and Sichuan Province Science and Technology Plan Support Projects

• Sichuan Province Major Science and Technology Project

  Clinical research project for high-purity human coagulation factor Ⅸ fills the gap in the province’s product offering, providing strong guarantee for the medication of hemophilia B patients.

Yuanda Shuyang has built up a significant patent portfolio, with 30 patents granted, including 13 valid invention patents, 6 international patents, 14 utility model patent certificates, and 3 appearance patent certificates. Intellectual property rights are secure for the next 30 years.